Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?

NCT ID NCT07662525

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether combining atorvastatin (a cholesterol-lowering drug), N-acetyl-L-cysteine (an antioxidant), and romiplostim (a platelet-boosting drug) can help adults with immune thrombocytopenia (ITP) who no longer respond to steroids. The goal is to see if this approach can keep platelet counts stable even after stopping all treatments. Fifty participants will receive the combination for 24 weeks, followed by a gradual taper of romiplostim, and will be monitored for sustained response off-treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atorvastatin, N-acetyl-L-cysteine, and romiplostim
What this could lead to
If successful, this combination could help people with hard-to-treat immune thrombocytopenia maintain safe platelet levels without needing long-term medication.
What could go wrong
This is a small, single-center study with no control group, so results may not apply broadly. The treatment involves multiple drugs and close monitoring, and some participants may not respond or may experience side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with primary ITP; * Aged ≥18 years; * Patients with treatment failure or relapse after first-line corticosteriod therapy for ITP; * Platelet count \<30×10⁹/L. Exclusion Criteria: * Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant; * Presence of active malignant tumors; * Active HBV, HCV or HIV infection; * Active infection requiring systematic treatment; * Leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis or other hematological disorders that may cause thrombocytopenia; * History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure; * AST \> 2 times the upper limit of normal (ULN), ALT \> 2×ULN, or TBIL ≥ 1.5×ULN; * eGFR \< 50 mL/min/1.73m²; * Any other subjects deemed ineligible for enrollment by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune thrombocytopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune thrombocytopenic purpura

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.